Literature DB >> 791105

Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys.

W E Bullock, R G Luke, C E Nuttall, D Bhathena.   

Abstract

Eleven patients with systemic mycotic infections were treated with amphotericin B, 1 mg/kg, on alternate days. Five patients also received mannitol (M), 1 g/kg, in the amphotericin infusion, while six served as controls (C). Renal function studies prior to therapy were repeated at a total cumulative amphotericin B dosage of 25 mg/kg; renal biopsies were obtained from 10 patients. Inulin and creatinine clearances decreased in both the C and M groups, significantly so in the latter. Urinary concentrating ability of five patients (2C, 3M) decreased as did the capacity of three (1C, 2M) to acidify urine after an acid load. Neither the peak and valley levels of amphotericin B in serum nor the urinary excretion thereof differed between the C and M groups. Striking vacuolization of smooth muscle cells, previously unrecognized, was observed in the media of arterioles and arteries in all renal biopsies. Tubular calcification was present in both groups. In summary, M therapy (1 g/kg) did not protect against the nephrotoxicity of amphotericin B. A unique lesion of the renal vasculature secondary to amphotericin B is described.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 791105      PMCID: PMC429787          DOI: 10.1128/AAC.10.3.555

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS.

Authors:  W T BUTLER; J E BENNETT; D W ALLING; P T WERTLAKE; J P UTZ; G J HILL
Journal:  Ann Intern Med       Date:  1964-08       Impact factor: 25.391

2.  AMPHOTERICIN B TOXICITY; GENERAL SIDE EFFECTS.

Authors:  J P UTZ
Journal:  Ann Intern Med       Date:  1964-08       Impact factor: 25.391

3.  NEPHROTOXIC TUBULAR DAMAGE AND CALCIUM DEPOSITION FOLLOWING AMPHOTERICIN B THERAPY.

Authors:  P T WERTLAKE; W T BUTLER; G J HILL; J P UTZ
Journal:  Am J Pathol       Date:  1963-09       Impact factor: 4.307

4.  AMPHOTERICIN B RENAL TOXICITY IN THE DOG.

Authors:  W T BUTLER; G J HILL; C F SZWED; V KNIGHT
Journal:  J Pharmacol Exp Ther       Date:  1964-01       Impact factor: 4.030

5.  EFFECTS OF HYPERTONIC MANNITOL ON RENAL VASCULAR RESISTANCE.

Authors:  A H GOLDBERG; L S LILIENFIELD
Journal:  Proc Soc Exp Biol Med       Date:  1965-07

6.  On the nephrotoxicity of amphotericin B in man.

Authors:  N H BELL; V T ANDRIOLE; S M SABESIN; J P UTZ
Journal:  Am J Med       Date:  1962-07       Impact factor: 4.965

7.  The excretion of acid in renal disease.

Authors:  O WRONG; H E DAVIES
Journal:  Q J Med       Date:  1959-04

8.  Colorimetric estimation of ketopentoses and ketohexoses.

Authors:  R G KULKA
Journal:  Biochem J       Date:  1956-08       Impact factor: 3.857

9.  The effect of mannitol on renal vascular resistance.

Authors:  R C Camishion; R W Solit; J Iida; W F Ballinger
Journal:  Surgery       Date:  1966-06       Impact factor: 3.982

10.  The toxic effects of amphotericin B in man.

Authors:  C W HOLEMAN; H EINSTEIN
Journal:  Calif Med       Date:  1963-08
View more
  20 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

3.  Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.

Authors: 
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

4.  Spinal blastomycosis--case report.

Authors:  C Krarup; C H Davis; L Symon; B N Harding; R J Hay
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-02       Impact factor: 10.154

5.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  C Tremblay; M Barza; C Fiore; F Szoka
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

7.  Therapy of fungal infections.

Authors:  D J Drutz
Journal:  Bull N Y Acad Med       Date:  1982-11

8.  Medial changes in arterial spasm induced by L-norepinephrine.

Authors:  I Joris; G Majno
Journal:  Am J Pathol       Date:  1981-12       Impact factor: 4.307

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

10.  Amphotericin B in the treatment of coccidioidomycosis.

Authors:  D J Drutz
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.